CACNA1C-IT2: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Target Name: CACNA1C-IT2

NCBI ID: G100874369

CACNA1C-IT2

Other Name(s): CACNA1C intronic transcript 2

CACNA1C-IT2: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Abstract:

CACNA1C-IT2, a novel gene expressed in the cardiac muscle, has been identified as a potential drug target and biomarker for the treatment of cardiovascular disease. The aim of this article is to review the current understanding of CACNA1C-IT2 and its potential as a drug target and biomarker.

Introduction:

Cardiovascular disease is a leading cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems. The development of new treatments and biomarkers for cardiovascular disease is crucial for improving patient outcomes. CACNA1C-IT2, a gene expressed in the cardiac muscle, has been identified as a potential drug target and biomarker for the treatment of cardiovascular disease.

Current Understanding of CACNA1C-IT2:

CACNA1C-IT2 is a member of the CACNA1C gene family, which is involved in the regulation of ion channels and cardiac contractions. The CACNA1C gene has four splice variants, each generating a unique protein. CACNA1C-IT2 is a splicing variant that is predominantly expressed in the cardiac muscle.

Studies have shown that CACNA1C-IT2 is involved in various physiological processes, including cardiac muscle contractions, heart rate, and ion channels. It has also been shown to play a role in the regulation of neurotransmitter release and cell signaling.

Potential Role as a Drug Target:

The potential role of CACNA1C-IT2 as a drug target is based on its involvement in various physiological processes that are relevant to cardiovascular disease. Several studies have shown that inhibition of CACNA1C-IT2 can improve cardiac function and reduce the risk of cardiovascular disease in animal models of hypertension and heart failure.

In addition, several drug candidates have been developed and are in clinical trials that target CACNA1C-IT2. These drugs include amuriprazole, a selective CACNA1C antagonist, and verapamil, an inhibitor of CACNA1C channels. Data from these studies have shown that these drugs have the potential to improve cardiac function and reduce the risk of cardiovascular disease in patients with cardiovascular disease.

Potential Role as a Biomarker:

CACNA1C-IT2 may also be used as a biomarker for the diagnosis and monitoring of cardiovascular disease. The expression of CACNA1C-IT2 has been shown to be affected by various cardiovascular risk factors, including age, sex, and lifestyle.

In addition, CACNA1C-IT2 has been shown to play a role in the regulation of cardiac hypertrophy and fibrosis, which are important biomarkers of cardiovascular disease. Therefore, the expression of CACNA1C-IT2 may be used as a marker for the diagnosis and monitoring of cardiovascular disease.

Conclusion:

CACNA1C-IT2 is a gene expressed in the cardiac muscle that has been shown to be involved in various physiological processes that are relevant to cardiovascular disease. The potential role of CACNA1C-IT2 as a drug target and biomarker for the treatment of cardiovascular disease is based on its involvement in these processes. Further studies are needed to fully understand the potential of CACNA1C-IT2 as a drug target and biomarker for the treatment of cardiovascular disease.

Protein Name: CACNA1C Intronic Transcript 2

The "CACNA1C-IT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNA1C-IT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets